246 related articles for article (PubMed ID: 17313465)
21. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis after stem cell transplantation: effective monitoring of CMV infection by quantitative analysis of CMV mRNA.
Ohta H; Matsuda Y; Tokimasa S; Sawada A; Kim JY; Sashihara J; Amo K; Miyagawa H; Tanaka-Taya K; Yamamoto S; Tano Y; Aono T; Yamanishi K; Okada S; Hara J
Bone Marrow Transplant; 2001 Jun; 27(11):1141-5. PubMed ID: 11551024
[TBL] [Abstract][Full Text] [Related]
22. Effect of a 14-day course of foscarnet on cytomegalovirus (CMV) blood markers in a randomized study of human immunodeficiency virus-infected patients with persistent CMV viremia. Agence National de Recherche du SIDA 023 Study Group.
Salmon-Céron D; Fillet AM; Aboulker JP; Gérard L; Houhou N; Carrière I; Ostinelli J; Vildé JL; Brun-Vézinet F; Leport C
Clin Infect Dis; 1999 Apr; 28(4):901-5. PubMed ID: 10825058
[TBL] [Abstract][Full Text] [Related]
23. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir.
Ippoliti C; Morgan A; Warkentin D; van Besien K; Mehra R; Khouri I; Giralt S; Gajewski J; Champlin R; Andersson B; Przepiorka D
Bone Marrow Transplant; 1997 Sep; 20(6):491-5. PubMed ID: 9313883
[TBL] [Abstract][Full Text] [Related]
24. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients.
Mylonakis E; Kallas WM; Fishman JA
Clin Infect Dis; 2002 May; 34(10):1337-41. PubMed ID: 11981729
[TBL] [Abstract][Full Text] [Related]
25. Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide.
Ehlert K; Groll AH; Kuehn J; Vormoor J
Klin Padiatr; 2006; 218(3):180-4. PubMed ID: 16688677
[TBL] [Abstract][Full Text] [Related]
26. Preemptive therapy with intravenous ganciclovir for the prevention of cytomegalovirus disease in lung transplant recipients.
Monforte V; Román A; Gavaldà J; Bravo C; Gispert P; Pahissa A; Morell F
Transplant Proc; 2005 Nov; 37(9):4039-42. PubMed ID: 16386621
[TBL] [Abstract][Full Text] [Related]
27. Impact of cytomegalovirus serostatus on outcome of unrelated cord blood transplantation for adults: a single-institute experience in Japan.
Tomonari A; Takahashi S; Ooi J; Tsukada N; Konuma T; Kato S; Kasahara S; Iseki T; Yamaguchi T; Tojo A; Asano S
Eur J Haematol; 2008 Mar; 80(3):251-7. PubMed ID: 18081702
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemically proven cytomegalovirus end-organ disease in solid organ transplant patients: clinical features and usefulness of conventional diagnostic tests.
Fica A; Cervera C; Pérez N; Marcos MA; Ramírez J; Linares L; Soto G; Navasa M; Cofan F; Ricart MJ; Pérez-Villa F; Pumarola T; Moreno A
Transpl Infect Dis; 2007 Sep; 9(3):203-10. PubMed ID: 17511827
[TBL] [Abstract][Full Text] [Related]
29. CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy.
Machado CM; Dulley FL; Boas LS; Castelli JB; Macedo MC; Silva RL; Pallota R; Saboya RS; Pannuti CS
Bone Marrow Transplant; 2000 Aug; 26(4):413-7. PubMed ID: 10982288
[TBL] [Abstract][Full Text] [Related]
30. [The prevention and treatment of cytomegalovirus infection after liver transplantation].
Zheng SS; Jiang ZJ; Xu X; Liang TB; Wang WL; Shen Y; Zhang M; Lu AW
Zhonghua Wai Ke Za Zhi; 2005 May; 43(9):584-6. PubMed ID: 15938930
[TBL] [Abstract][Full Text] [Related]
31. [Evaluation of viral load and antigenemia as markers for relapse cytomegalovirus infection in renal transplant recipients].
Franco A; Serrano R; Gimeno A; de Juan J; Merino E; Jiménez del Cerro L; Olivares J
Nefrologia; 2007; 27(2):202-8. PubMed ID: 17564566
[TBL] [Abstract][Full Text] [Related]
32. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation.
Bacigalupo A; Bregante S; Tedone E; Isaza A; Van Lint MT; Trespi G; Occhini D; Gualandi F; Lamparelli T; Marmont AM
Transplantation; 1996 Aug; 62(3):376-80. PubMed ID: 8779686
[TBL] [Abstract][Full Text] [Related]
33. Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen.
Thomas LD; Milstone AP; Miller GG; Loyd JE; Stephen Dummer J
Clin Transplant; 2009; 23(4):476-83. PubMed ID: 19453645
[TBL] [Abstract][Full Text] [Related]
34. Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation.
Battiwalla M; Paplham P; Almyroudis NG; McCarthy A; Abdelhalim A; Elefante A; Smith P; Becker J; McCarthy PL; Segal BH
Transpl Infect Dis; 2007 Mar; 9(1):28-32. PubMed ID: 17313468
[TBL] [Abstract][Full Text] [Related]
35. Treatment of cytomegalovirus esophagitis in patients with acquired immune deficiency syndrome: a randomized controlled study of foscarnet versus ganciclovir. The Italian Cytomegalovirus Study Group.
Parente F; Bianchi Porro G
Am J Gastroenterol; 1998 Mar; 93(3):317-22. PubMed ID: 9517631
[TBL] [Abstract][Full Text] [Related]
36. Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual-strain cytomegalovirus coinfection.
Rodriguez J; Casper K; Smallwood G; Stieber A; Fasola C; Lehneman J; Heffron T
Liver Transpl; 2007 Oct; 13(10):1396-400. PubMed ID: 17902124
[TBL] [Abstract][Full Text] [Related]
37. Half-dose ganciclovir preemptive treatment of cytomegalovirus infection after pediatric allogeneic hematopoietic stem cell transplantation.
Ju HY; Kang HJ; Hong CR; Lee JW; Kim H; Park KD; Shin HY; Park JD; Choi EH; Lee HJ; Ahn HS
Transpl Infect Dis; 2016 Jun; 18(3):396-404. PubMed ID: 27041364
[TBL] [Abstract][Full Text] [Related]
38. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy.
Alberú J; Morales-Buenrostro LE; Correa-Rotter R; Muñoz-Trejo T; Zúñiga-Varga J; Cuéllar-González JV; Mayorga-Madrigal H; Vanegas-Carrero R; Aranda F; Rodríguez-Romo R; Herrera-Garcia C; González-Michaca L; Sierra-Madero JG
Rev Invest Clin; 2008; 60(5):365-74. PubMed ID: 19227433
[TBL] [Abstract][Full Text] [Related]
39. Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients.
Bacigalupo A; Boyd A; Slipper J; Curtis J; Clissold S
Expert Rev Anti Infect Ther; 2012 Nov; 10(11):1249-64. PubMed ID: 23167560
[TBL] [Abstract][Full Text] [Related]
40. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation.
Reusser P; Einsele H; Lee J; Volin L; Rovira M; Engelhard D; Finke J; Cordonnier C; Link H; Ljungman P;
Blood; 2002 Feb; 99(4):1159-64. PubMed ID: 11830461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
